Investors Buy High Volume of Call Options on Sunesis Pharmaceuticals (SNSS)

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) was the recipient of some unusual options trading on Thursday. Investors purchased 597 call options on the company. This represents an increase of approximately 818% compared to the typical daily volume of 65 call options.

A number of research analysts have recently issued reports on SNSS shares. Wells Fargo & Co upgraded Sunesis Pharmaceuticals from a “market perform” rating to an “outperform” rating and decreased their target price for the company from $2.86 to $2.48 in a research report on Monday, December 11th. Cantor Fitzgerald set a $3.00 target price on Sunesis Pharmaceuticals and gave the company a “hold” rating in a research report on Monday, December 11th. Cowen reiterated a “hold” rating on shares of Sunesis Pharmaceuticals in a research report on Thursday, November 2nd. UBS Group assumed coverage on Sunesis Pharmaceuticals in a research note on Monday, November 20th. They issued an “outperform” rating for the company. Finally, Oppenheimer assumed coverage on Sunesis Pharmaceuticals in a research note on Thursday, December 14th. They issued a “buy” rating and a $7.00 price objective for the company. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Sunesis Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $3.75.

Sunesis Pharmaceuticals (NASDAQ SNSS) opened at $6.79 on Friday. Sunesis Pharmaceuticals has a 52 week low of $1.82 and a 52 week high of $7.25. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of -0.34. The company has a market capitalization of $239.39, a price-to-earnings ratio of -3.88 and a beta of 1.71.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its stake in Sunesis Pharmaceuticals by 9.5% in the 4th quarter. BlackRock Inc. now owns 130,573 shares of the biopharmaceutical company’s stock valued at $482,000 after purchasing an additional 11,351 shares during the last quarter. Wells Fargo & Company MN raised its stake in Sunesis Pharmaceuticals by 77.4% in the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 18,254 shares during the last quarter. Vanguard Group Inc. raised its stake in Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after purchasing an additional 23,819 shares during the last quarter. Geode Capital Management LLC raised its stake in Sunesis Pharmaceuticals by 105.2% in the 4th quarter. Geode Capital Management LLC now owns 125,489 shares of the biopharmaceutical company’s stock valued at $463,000 after purchasing an additional 64,343 shares during the last quarter. Finally, Virtu KCG Holdings LLC acquired a new position in Sunesis Pharmaceuticals in the 2nd quarter valued at $208,000. 39.64% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Investors Buy High Volume of Call Options on Sunesis Pharmaceuticals (SNSS)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/23/investors-buy-high-volume-of-call-options-on-sunesis-pharmaceuticals-snss.html.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply